Abstract
Background The genetic landscape of cardiometabolic risk factors has been explored extensively. However, insight in the effects of genetic variation on these risk factors over the life course is sparse. Here, we performed genome-wide interaction studies (GWIS) on different cardiometabolic risk factors to identify age-specific genetic risks.
Methods This study included 270,276 unrelated European-ancestry participants from the UK Biobank (54.2% women, a median age of 58 [interquartile range (IQR): 50, 63] years). GWIS models with interaction terms between genetic variants and age were performed on apolipoprotein B (ApoB), low-density lipoprotein-cholesterol (LDL-C), log-transformed triglycerides (TG), body mass index (BMI), and systolic blood pressure (SBP). Replication was subsequently performed in the Copenhagen General Population Study (CGPS) and the Estonian Biobank (EstBB).
Results Multiple lead variants were identified to have genome-wide significant interactions with age (Pinteraction <1e-08). In detail, rs429358 (tagging APOE4) was identified for ApoB (Pinteraction = 9.0e-14) and TG (Pinteraction = 5.4e-16). Three additional lead variants were identified for ApoB: rs11591147 (R46L in PCSK9, Pinteraction= 3.9e-09), rs34601365 (near APOB, Pinteraction = 8.4e-09), and rs17248720 (near LDLR, Pinteraction = 2.0e-09). Effect sizes of the identified lead variants were generally closer to the null with increasing age. No variant-age interactions were identified for LDL-C, SBP and BMI. The significant interactions of rs429358 with age on ApoB and TG were replicated in both CGPS and EstBB.
Conclusions The majority of genetic effects on cardiometabolic risk factors remains relatively constant over age, with the noted exceptions of specific genetic effects on ApoB and TG.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the China Scholarship Council (CSC; no. 202106240064; to L Ao).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of North-West Multicenter Research gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Estonian Biobank Research Team: Andres Metspalu, Lili Milani, Tõnu Esko, Reedik Mägi, Mari Nelis and Georgi Hudjashov
Data Availability
All data produced in the present study are available upon reasonable request to the authors
